Emerging Technology Reports

The Emerging Technology Report provides regular updates about emerging and potentially disruptive technologies that are likely to have a significant impact in healthcare. This “early warning” report monitors new health technologies from 6 months to 2 years within a regulatory submission and tracks those as they go through clinical trial development and the regulatory approval process.

For each emerging technology, our analysts describe the technology and intended use, its prospects relative to the regulatory process and FDA information, competing technologies, relevant clinical guidelines, high-level look at the evidence such as published abstracts in the medical literature and available meeting abstracts, and available clinical trials.

Nanostim Leadless Pacemaker

A transcatheter, miniaturized, single-chamber, leadless cardiac pacemaker proposed to reduce risk for lead-related complications associated with conventional pacemakers.

BioFreedom Drug-Coated Stent

A polymer-free biolimus A9–coated stent for treatment of coronary artery disease in patients with high bleeding risk.

Zurampic (Lesinurad)

An oral first-in-class selective uric acid reabsorption inhibitor proposed for second-line use in combination with a xanthine oxidase inhibitor to treat hyperuricemia associated with gout.